UY35795A - Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran - Google Patents
Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatranInfo
- Publication number
- UY35795A UY35795A UY0001035795A UY35795A UY35795A UY 35795 A UY35795 A UY 35795A UY 0001035795 A UY0001035795 A UY 0001035795A UY 35795 A UY35795 A UY 35795A UY 35795 A UY35795 A UY 35795A
- Authority
- UY
- Uruguay
- Prior art keywords
- dabigatran
- acilglucurónidos
- neutralize
- antibodies
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a las moléculas de anticuerpo contra anticoagulantes, en particular dabigatran, y su uso como antídotos de tales anticoagulantes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361895443P | 2013-10-25 | 2013-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35795A true UY35795A (es) | 2015-04-30 |
Family
ID=51795624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035795A UY35795A (es) | 2013-10-25 | 2014-10-24 | Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran |
Country Status (7)
Country | Link |
---|---|
US (1) | US9499633B2 (es) |
EP (1) | EP3060583A1 (es) |
JP (1) | JP2016539926A (es) |
AR (1) | AR098198A1 (es) |
TW (1) | TW201609816A (es) |
UY (1) | UY35795A (es) |
WO (1) | WO2015059159A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6887613B2 (ja) * | 2016-03-31 | 2021-06-16 | 国立大学法人東北大学 | がん微小環境を標的とした抗ポドカリキシン抗体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR079944A1 (es) * | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
SG193552A1 (en) * | 2011-03-30 | 2013-11-29 | Boehringer Ingelheim Int | Anticoagulant antidotes |
-
2014
- 2014-10-21 EP EP14789547.8A patent/EP3060583A1/en not_active Withdrawn
- 2014-10-21 JP JP2016525867A patent/JP2016539926A/ja active Pending
- 2014-10-21 WO PCT/EP2014/072579 patent/WO2015059159A1/en active Application Filing
- 2014-10-23 US US14/521,499 patent/US9499633B2/en active Active
- 2014-10-24 AR ARP140104022A patent/AR098198A1/es unknown
- 2014-10-24 TW TW103136872A patent/TW201609816A/zh unknown
- 2014-10-24 UY UY0001035795A patent/UY35795A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2016539926A (ja) | 2016-12-22 |
AR098198A1 (es) | 2016-05-18 |
WO2015059159A1 (en) | 2015-04-30 |
EP3060583A1 (en) | 2016-08-31 |
US9499633B2 (en) | 2016-11-22 |
US20150118225A1 (en) | 2015-04-30 |
TW201609816A (zh) | 2016-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150329A (es) | Inmunoglobulinas heterodiméricas | |
CL2015001924A1 (es) | Anticuerpos anti-pdgfr-beta y usos relacionados. | |
ECSP12012105A (es) | Antídotos de Anticoagulantes | |
CL2016001102A1 (es) | Anticuerpos anti-claudina novedosos y métodos de uso. | |
CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
CL2016000251A1 (es) | Anticuerpos anti-activina y usos de los mismos | |
UY34680A (es) | Anticuerpos humanos anti-cd27, métodos, y usos | |
BR112015014063A2 (pt) | anticorpos anti-b7-h4 humano e seus usos. | |
EA201691214A1 (ru) | Антитела к cd33 и иммуноконъюгаты | |
WO2014197849A3 (en) | Anti-c10orf54 antibodies and uses thereof | |
UY34876A (es) | Anticuerpos anti-egfr y usos de los mismos | |
UY34782A (es) | Anticuerpos humanos para fel d1 y métodos para usarlos. | |
CL2014001984A1 (es) | Anticuerpos humanizados que reconozen alfa-sinucleína; metodo de produccion y sus usos. | |
BR112016000106A2 (pt) | anticorpos c1q do fator anti-complemento e usos dos mesmos | |
CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
UY34721A (es) | Anticuerpos anti-hla-b*27 y usos de éstos. | |
CL2014001640A1 (es) | Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo. | |
UY34652A (es) | Anticuerpos humanos frente a toxinas de clostridium difficile | |
BR112016013562A2 (pt) | Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas | |
BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
CL2014002616A1 (es) | Anticuerpos anti-baff-anti-il-17 biespecíficos; composiciones que lo contienen y sus usos. | |
ECSP13012997A (es) | Antídotos anticoagulantes | |
MA43814A (fr) | Anticorps anti-gitr, méthodes et utilisations | |
CL2016001147A1 (es) | Anticuerpos específicos para fcrn. |